The Heart Drug That Just Crashed a Party It Wasn't Invited To

That's the gap Cytokinetics just stepped into.

What the ACACIA-HCM Trial Actually Showed

The Phase 3 ACACIA-HCM trial enrolled patients with symptomatic non-obstructive HCM and tested aficamten against placebo over 36 weeks. It had two co-primary endpoints (the two things it absolutely had to prove to count as a win).

First: patient-reported quality of life, measured by something called the KCCQ-CSS score. Think of it as a standardized questionnaire that captures how much your heart condition is wrecking your daily life. Aficamten patients improved by 11.4 points versus 8.4 for placebo, a statistically significant difference (p=0.021).

Second: peak exercise capacity, measured by how much oxygen your body uses during maximum exertion (pVO₂). Aficamten patients gained 0.64 mL/kg/min, while placebo patients actually declined by 0.03 mL/kg/min. That gap was highly significant (p=0.003).

Both primary endpoints met. Both statistically significant. That's the kind of clean result that makes regulatory reviewers smile.

Several secondary measures also tilted in aficamten's favor, including improvements in heart failure functional class (NYHA class), a composite exercise test score, and NT-proBNP, a blood marker that rises when the heart is under stress. However, two secondary endpoints (left atrial volume and time to first cardiovascular event) did not reach statistical significance. Not everything was a home run, but the starting lineup delivered.

Why This Is a Bigger Deal Than It Looks

The science here is genuinely interesting. Aficamten works by binding to cardiac myosin, the molecular motor that makes heart muscle contract. It prevents myosin from entering its force-producing state, essentially telling an overenthusiastic engine to ease off the gas. In obstructive HCM, this makes intuitive sense: reduce the force, reduce the obstruction.

But in non-obstructive HCM, there's no obstruction to reduce. The rationale is subtler. By dialing down excessive contractility, aficamten appears to help the heart relax and fill more effectively, improving symptoms even without a gradient to relieve. It's like discovering that a volume knob doesn't just prevent distortion; it also makes the whole song sound better.

Cytokinetics reported no new safety signals from the trial, which matters because these drugs can reduce heart pumping function (ejection fraction) too aggressively if not monitored carefully. Aficamten's relatively short half-life of about 80 hours and rapid reversibility within 24 to 48 hours give it a practical safety advantage; if something goes wrong, the drug clears out quickly.

The Competitive Chessboard

This trial doesn't just matter for patients. It reshapes the commercial landscape.

Right now, the cardiac myosin inhibitor market is a two-horse race: Bristol Myers Squibb's mavacamten (the incumbent, approved first, with deeper real-world experience) and Cytokinetics' aficamten (the newer challenger with emerging tolerability advantages). Both are approved for obstructive HCM. Indirect comparisons suggest mavacamten may edge out aficamten on raw efficacy for reducing obstruction gradients, while aficamten looks better on safety and fewer treatment interruptions.

But ACACIA-HCM just gave Cytokinetics something mavacamten doesn't have: positive pivotal data in non-obstructive HCM. Bristol Myers Squibb ran a pivotal Phase 3 trial (ODYSSEY-HCM) of mavacamten in non-obstructive HCM, but it failed to meet its primary endpoints. If Cytokinetics files its planned supplemental application in Q4 2026 and gets approved, aficamten would be the first (and only) targeted therapy for a patient population that's potentially larger than the obstructive market it already serves.

That's not just a label expansion. That's a whole new revenue stream landing on the balance sheet.

What Comes Next

Cytokinetics has said it plans to submit a supplemental NDA in Q4 2026 based on these results. The NEJM publication and Hot Line presentation at ESC give the data maximum visibility and credibility, which tends to grease the regulatory wheels.

The simultaneous publication timing is worth noting. Getting your pivotal trial into the New England Journal of Medicine on the same day you present at the world's biggest cardiology conference isn't an accident. It's a deliberate strategy to make the data as hard to ignore as possible, for regulators, for physicians, and for investors.

For the roughly one-third of HCM patients living without a targeted therapy, this trial represents something they haven't had before: proof that a drug designed to fix their underlying problem actually works. Whether that translates into an approval is still months away. But for the first time, the path looks real.

One Shot to Rewrite Your Cholesterol Forever

CRISPR Therapeutics just showed that a single IV infusion can slash cholesterol and triglycerides for at least a year by permanently editing a gene in liver cells. The one-year Phase 1a data for CTX310 are stunning, but the jump from 15 patients to the real world is where things get interesting.